Navigation Links
Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
Date:2/3/2012

CHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common stock at a price to the public of $6.00 per share.  Cempra also has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares to cover over-allotments, if any.

Shares of Cempra's common stock will trade on the NASDAQ Global Market under the symbol "CEMP" beginning on February 3, 2012. The closing of the offering is expected to occur on February 8, 2012, subject to the satisfaction of customary closing conditions. 

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering.  Needham & Company, LLC is acting as co-manager.

The offering of these securities will be made only by means of a prospectus.  A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. 

A copy of the prospectus relating to the offering may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Leerink Swann LLC, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling (800) 808-7525; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling (631) 274-2806.  The final prospectus, when it is available, also may be obtained on the Securities and Exchange Commission's Web site at www.sec.gov.

About Cempra

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Contact:

Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com

Dr. Prabhavathi Fernandes
President and Chief Executive Officer
(919) 467-1716
pfernandes@cempra.com


'/>"/>
SOURCE Cempra, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
2. Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
3. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
4. Perrigo Company Announces Quarterly Dividend
5. BioParadox Announces Partnership with Fogarty Institute for Innovation
6. Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
7. Nautilus Neurosciences Announces New Patent Issued
8. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
9. Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
10. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
11. RemedyMD Announces Investigate Cell Therapy, a Revolutionary Research Management System for Blood and Marrow Transplant Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):